{
  "abstract": "Background and Importance Chemotherapy desensitisation (CD) enables safe re-administration of oncological drugs in patients with previous hypersensitivity reactions (HSR). These reactions often lead to discontinuation of first-line therapies, so implementing CD protocols allows patients to receive optimal therapy while minimising risk. However, evidence in routine clinical practice remains limited. In our hospital, CD is performed according to the standard Boston (Castells et al.) 12-step, 3-bag rapid desensitisation protocol, with progressive concentrations of 1:100, 1:10, 1:1. All infusions are prepared and verified by the Hospital Pharmacy Service.Aim and Objectives The primary endpoint was to evaluate the safety and tolerance of CD, defined as the completion of planned cycles. The secondary endpoint was to analyse the relationship between allergy testing and the indication for desensitisation.Material and Methods Observational, descriptive and retrospective study including patients with HSR to chemotherapy who subsequently received CD, between January 2012-July 2025, in a university hospital. Variables included age, sex, tumour type, drug desensitised, HSR type, cycles prior to HSR, tolerance (based on cycles under CD and reason for discontinuation) and allergy testing results.Results 106 patients were included (mean age 58±12.6 years), 89 women (84%), 17 men (16%). Tumour distribution was breast (31.1%), gynaecological (31.1%), digestive (27.4%), pulmonary (7.5%), head and neck (1.9%) and sarcoma (0.9%). The most frequently desensitised drugs were paclitaxel (45.4%), oxaliplatin (24.5%), carboplatin (14.1%), docetaxel (9.4%), cisplatin (4.7%), others (<1% each). 96 patients (90.6%) suffered an immediate HSR, 10 patients (9.4%) a delayed HSR. Mean cycles prior to HSR were 2±1.8, mean cycles under CD were 4±3.2.Regarding tolerance, 42 patients (39.6%) successfully completed the planned cycles, 11 (10.4%) discontinued due to HSR despite desensitisation, and 53 (50%) interrupted the treatment due to progression or death. Concerning allergy testing, 95 patients (89.6%) were tested before CD, with only 16 (16.8%) positives.Conclusion and Relevance CD showed to be a safe strategy, enabling patients with HSR to continue first-line treatments. The low correlation between allergy test results and indication for CD supports its use based on clinical judgement rather than test positivity. These findings emphasise the value of structured desensitisation protocols and highlight the essential role of hospital pharmacists in ensuring treatment continuity and safety.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "L Coiduras Del Olmo"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "G Pinilla Lebrero"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "E García Martín"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "M Loysele Susmozas"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "E Martín Vega"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "J Anaya García"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "R Fuente Irigoyen"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "B García De Santiago"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "A Martínez Hernández"
    }
  ],
  "title": "5PSQ-054 From reaction to tolerance: hospital pharmacy experience with chemotherapy desensitisation",
  "uid": "aeeffdb1-d564-533a-a33e-22f6832e871b"
}